×
About Us
Overview
Our Leadership
Board of Directors
Scientific Advisory Board
Cell Manufacturing Advisory Board
Strategic Partners
Technology
Allogeneic Cell Therapy Platform
Oncolytic Virus Combinations
CD30 CAR-T Cell Therapy
Manufacturing
Pipeline
TT11X Allogeneic CD30 CAR EBVSTs
TT16 HER2 CAR Ts + CAdVEC
TT11 CD30 CAR Ts
TT11 CD30 CAR Ts + Nivolumab
Expanded Access
Scientific Publications
Investors & Media
Press Releases & Events
Interviews
Careers
Contact Us
×
What are you looking for?
Search for:
About Us
Overview
Our Leadership
Board of Directors
Scientific Advisory Board
Cell Manufacturing Advisory Board
Strategic Partners
Technology
Allogeneic Cell Therapy Platform
Oncolytic Virus Combinations
CD30 CAR-T Cell Therapy
Manufacturing
Pipeline
TT11X Allogeneic CD30 CAR EBVSTs
TT16 HER2 CAR Ts + CAdVEC
TT11 CD30 CAR Ts
TT11 CD30 CAR Ts + Nivolumab
Expanded Access
Scientific Publications
Investors & Media
Press Releases & Events
Interviews
Careers
Contact Us
Interview Series: In Pursuit of Cancer Cure: Conversations with Immunotherapy Advocates – Dr Malcolm Brenner
by
tessathe
on
April 12, 2019
in
news-videos
<< Back to Interviews
Previous Reading
Our Scientific Co-founder, Dr Malcolm Brenner Shares the Story about the Early Days of Tessa and its Scientific Foundation
Next Reading
Tessa Therapeutics, in Collaboration with Baylor College of Medicine, Presents Preclinical Results Showing Enhanced T Cell Responses Against HER2-Positive Solid Tumors Using Novel Combination CAR T Cell Therapy